Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases. We report successful allogeneic bone marrow transplantation in two siblings with this disease from their sister, and their long term follow-up. We used reduced doses of cyclophosphamide and busulfan for conditioning instead of total body irradiation. Also, we report late adverse effects of transplantation which are not distinguishable from the natural course of disease. Keywords: allogeneic bone marrow transplantation; constitutional anemia; dyskeratosis congenita Dyskeratosis congenita is a rare congenital syndrome characterized by atrophy and reticular pigmentation of skin, dystrophy of nails, 1 leukoplakia together with multi-system ectodermal and some mesodermal changes. Skin changes are typically located on the upper torso, neck and face, although the extremities may also be involved. Other manifestations of dyskeratosis congenita may be some other epithelial changes such as gingival disorders, dysphagia due to esophageal strictures, skeletal abnormality, aplastic anemia, 2 mental deficiency and hypersplenism. Severe aplastic anemia appears between the ages of 5 and 10 years.
Dyskeratosis congenita is a rare congenital syndrome characterized by atrophy and reticular pigmentation of skin, dystrophy of nails, 1 leukoplakia together with multi-system ectodermal and some mesodermal changes. Skin changes are typically located on the upper torso, neck and face, although the extremities may also be involved. Other manifestations of dyskeratosis congenita may be some other epithelial changes such as gingival disorders, dysphagia due to esophageal strictures, skeletal abnormality, aplastic anemia, 2 mental deficiency and hypersplenism. Severe aplastic anemia appears between the ages of 5 and 10 years. 3 Most of the cases transmit as an X-linked recessive inheritance pattern, although autosomal recessive 4 and autosomal dominant transmission 5 have also been reported. Results of allogeneic bone marrow transplantation in these patients have been relatively poor due to early and late complications. [6] [7] [8] [9] [10] We describe the effect of bone marrow transplantation for aplastic anemia in two siblings with dyskeratosis congenita from a single donor. The other brother of these two siblings had died due to bone marrow failure and dyskeratosis congenita previously. The parents of patients were not first cousins and were phenotypically normal. Case report
Case 1
Patient 1 was an 18-year-old man with dyskeratosis congenita with reticular pigmentation, nail dystrophy, leukoplakia and marrow failure. He had received oxymetholone before BMT, with a history of frequent blood and platelet transfusion. Pulmonary function tests before bone marrow transplantation were normal. His bone marrow was hypoplastic and peripheral blood indices showed pancytopenia (Table 1) .
His conditioning regimen was cyclophosphamide 20 mg/kg/day for 4 days and busulfan 0.2 mg/kg/day for 4 days. Transplantation was carried out with infusion of 4.6 × 10 8 mononuclear cells per kilogram of body weight from bone marrow of his HLA-identical healthy sister. We used methotrexate and cyclosporin for GVHD prophylaxis and mild skin and gastrointestinal acute GVHD occurred after transplantation. He was discharged from hospital 37 days after marrow transplantation. On further follow-up, only his skin showed erythematous lesions and desquamation of his face, which was not possible to differentiate between chronic GVHD and dyskeratosis. He suffered from both esophageal stenosis, below the upper esophageal sphincter that was dilated, and dry eyes.
He was well without any respiratory symptom and his CBC results were normal at the last visit about 6 years after bone marrow transplantation (Table 1) .
Case 2
Patient 2 was a 21-year-old girl who presented just like her brother (case 1) with similar mucocutanous and nail changes. Her last CBC before transplantation showed pancytopenia (Table 1) . Pulmonary function tests were normal. The conditioning regimen used was similar to patient 1. Transplantation was carried out with infusion of 4 × 10 8 mononuclear cells/kg from her HLA-identical sister. GVHD prophylaxis was like patient 1 and mild skin and gastrointestinal acute GVHD occurred.
She left hospital in good general condition, 34 days after transplantation. Her skin lesions on subsequent follow-up were erythematous with localized scleroderma on her extremities, and nail changes were evident (Figure 1 ). Also 300 Table 1 Pre-and post-transplantation CBC she suffered from dysphagea due to esophageal stricture that was dilated but recurred 2 years later. Again endoscopic dilatation was performed. At the last visit, 5 years after BMT, she was well without any respiratory symptoms and CBC values were normal (Table 1) .
Discussion
We describe the successful use of bone marrow transplantation to reverse bone marrow hypoplasia in two siblings with this rare skin disorder. Because of similarities between this disease and Fanconi's anemia, we used a reduced dose of cyclophosphamide and busulfan, instead of total body irradiation, to reduce the risk of post-BMT complications, 11 without any impact on bone marrow transplantation results. In previous reports in Fanconi's anemia, cyclophosphamide with or without thoraco-abdominal irradiation was used 12, 13 and there is little experience with busulfan. In addition, irradiation may cause late vascular complications after bone marrow transplantation for dyskeratosis 7 and we suggest that the good results obtained by our team is due to avoidance of TBI in conditioning. [6] [7] [8] [9] [10] In our patients reduced dose of busulfan was well tolerated with no major side-effects. Also, differentiation of skin and GI lesions of this disease from chronic GVHD is not possible.
In summary, with an appropriate conditioning regimen, BMT seems to be a feasible treatment for bone marrow hypoplasia in dyskeratosis congenita.
